Cover Image
市場調查報告書

Viventia Biotechnologies Inc.:產品平台分析

Viventia Biotechnologies Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 224736
出版日期 內容資訊 英文 28 Pages
訂單完成後即時交付
價格
Back to Top
Viventia Biotechnologies Inc.:產品平台分析 Viventia Biotechnologies Inc. - Product Pipeline Review - 2015
出版日期: 2015年07月15日 內容資訊: 英文 28 Pages
簡介

Viventia Biotechnologies Inc.是針對為癌症所苦的患者開發新世代單株抗體產品的生物醫藥品企業。

本報告提供Viventia Biotechnologies Inc.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Viventia Biotechnologies Inc.的基本資料

  • Viventia Biotechnologies Inc.概要
  • 主要資訊
  • 企業資料

Viventia Biotechnologies Inc.:R&D概要

  • 主要的治療範圍

Viventia Biotechnologies Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Viventia Biotechnologies Inc.:開發中產品概況

  • 後期階段產品開發中產品
    • 第Ⅲ相的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第Ⅱ相的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Viventia Biotechnologies Inc.:藥物簡介

  • oportuzumab monatox
  • VB-6756
  • VB-6901
  • VBX-008
  • VBx-011
  • VBX-050

Viventia Biotechnologies Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Viventia Biotechnologies Inc.:暫停中的計劃

Viventia Biotechnologies Inc.:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07296CDB

Summary

Global Markets Direct's, 'Viventia Biotechnologies Inc. - Product Pipeline Review - 2015', provides an overview of the Viventia Biotechnologies Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Viventia Biotechnologies Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Viventia Biotechnologies Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Viventia Biotechnologies Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Viventia Biotechnologies Inc.'s pipeline products

Reasons to buy

  • Evaluate Viventia Biotechnologies Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Viventia Biotechnologies Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Viventia Biotechnologies Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Viventia Biotechnologies Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Viventia Biotechnologies Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Viventia Biotechnologies Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Viventia Biotechnologies Inc. Snapshot
    • Viventia Biotechnologies Inc. Overview
    • Key Information
    • Key Facts
  • Viventia Biotechnologies Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Viventia Biotechnologies Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Viventia Biotechnologies Inc. - Pipeline Products Glance
    • Viventia Biotechnologies Inc. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Viventia Biotechnologies Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Viventia Biotechnologies Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Viventia Biotechnologies Inc. - Drug Profiles
    • oportuzumab monatox
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VB-6756
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VB-6901
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VBX-008
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VBx-011
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VBX-050
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Viventia Biotechnologies Inc. - Pipeline Analysis
    • Viventia Biotechnologies Inc. - Pipeline Products by Target
    • Viventia Biotechnologies Inc. - Pipeline Products by Route of Administration
    • Viventia Biotechnologies Inc. - Pipeline Products by Molecule Type
    • Viventia Biotechnologies Inc. - Pipeline Products by Mechanism of Action
  • Viventia Biotechnologies Inc. - Recent Pipeline Updates
  • Viventia Biotechnologies Inc. - Dormant Projects
  • Viventia Biotechnologies Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Viventia Biotechnologies Inc., Key Information
  • Viventia Biotechnologies Inc., Key Facts
  • Viventia Biotechnologies Inc. - Pipeline by Indication, 2015
  • Viventia Biotechnologies Inc. - Pipeline by Stage of Development, 2015
  • Viventia Biotechnologies Inc. - Monotherapy Products in Pipeline, 2015
  • Viventia Biotechnologies Inc. - Phase III, 2015
  • Viventia Biotechnologies Inc. - Phase II, 2015
  • Viventia Biotechnologies Inc. - Preclinical, 2015
  • Viventia Biotechnologies Inc. - Pipeline by Target, 2015
  • Viventia Biotechnologies Inc. - Pipeline by Route of Administration, 2015
  • Viventia Biotechnologies Inc. - Pipeline by Molecule Type, 2015
  • Viventia Biotechnologies Inc. - Pipeline Products by Mechanism of Action, 2015
  • Viventia Biotechnologies Inc. - Recent Pipeline Updates, 2015
  • Viventia Biotechnologies Inc. - Dormant Developmental Projects,2015

List of Figures

  • Viventia Biotechnologies Inc. - Pipeline by Top 10 Indication, 2015
  • Viventia Biotechnologies Inc. - Pipeline by Stage of Development, 2015
  • Viventia Biotechnologies Inc. - Monotherapy Products in Pipeline, 2015
  • Viventia Biotechnologies Inc. - Pipeline by Top 10 Target, 2015
  • Viventia Biotechnologies Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Viventia Biotechnologies Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Viventia Biotechnologies Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top